Hofseth BioCare ASA: SECOND QUARTER 2026 FINANCIAL REPORT

HBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2 2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK 0.6 million (positive NOK 1.3 million in Q2 2025), excluding non-recurring and strategic development costs such as clinical trials and R&D expenses, and Berkåk project costs. The operating result (EBIT) was negative NOK 12.9 (-14.9) in the last quarter. Cash and cash equivalents increased by NOK 59.7 million during the quarter, ending at NOK 108.0 million as of 30 June 2026 (68.0). Including available credit facilities, total liquidity was NOK 109.0 million at quarter-end (76.5).